28 related articles for article (PubMed ID: 1540881)
1. Refractory Hypotension and Rapid Onset AKI: Deadly Complication After Doxorubicin and Mitomycin-C HIPEC Therapy.
Das AK; Sharma A; Kothari N; Choudhary R
Indian J Surg Oncol; 2023 Jun; 14(Suppl 1):189-191. PubMed ID: 37359929
[No Abstract] [Full Text] [Related]
2. HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases.
Dozono H; Yanazume S; Nakamura H; Etrych T; Chytil P; Ulbrich K; Fang J; Arimura T; Douchi T; Kobayashi H; Ikoma M; Maeda H
Target Oncol; 2016 Feb; 11(1):101-6. PubMed ID: 26194363
[TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy for hormone-refractory prostate cancer: Association of Adriamycin and ifosfamide.
Toulmonde M; Démolis P; Houédé N
Exp Ther Med; 2010 Nov; 1(6):1005-1011. PubMed ID: 22993633
[TBL] [Abstract][Full Text] [Related]
4. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group.
Winquist E; Waldron T; Berry S; Ernst DS; Hotte S; Lukka H
BMC Cancer; 2006 May; 6():112. PubMed ID: 16670021
[TBL] [Abstract][Full Text] [Related]
5. Treatment options in hormone-refractory prostate cancer: current and future approaches.
Harris KA; Reese DM
Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129
[TBL] [Abstract][Full Text] [Related]
6. Can prostate-specific antigen be used as a valid end point to determine the efficacy of chemotherapy for advanced prostate cancer?
Seckin B; Anthony CT; Murphy B; Steiner MS
World J Urol; 1996; 14 Suppl 1():S26-9. PubMed ID: 8738407
[TBL] [Abstract][Full Text] [Related]
7. Intra-arterial chemotherapy using a reservoir for endocrine-refractory prostate cancer.
Kuriyama M; Takeuchi T; Takahashi Y; Takeda A; Ishihara S; Ozeki S; Ueno K; Taniguchi M; Yamamoto N; Nagatani Y
Cancer Chemother Pharmacol; 1994; 35 Suppl():S27-30. PubMed ID: 7527734
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for endocrine-therapy-refractory prostate cancer.
Akimoto S; Ohki T; Akakura K; Masai M; Shimazaki J
Cancer Chemother Pharmacol; 1994; 35 Suppl():S18-22. PubMed ID: 7527733
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of hormonally unresponsive prostatic carcinoma.
deKernion JB; Lindner A
Urol Clin North Am; 1984 May; 11(2):319-26. PubMed ID: 6233779
[TBL] [Abstract][Full Text] [Related]
10. [A current overview of chemotherapy in advanced gastric cancer].
Ogawa M
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2161-8. PubMed ID: 2660747
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil.
Laurie JA; Hahn RG; Therneau TM; Patel SR; Mailliard JA; Windschitl HE; Twito DI; Morton RF; Krook JE
Cancer; 1992 Mar; 69(6):1440-4. PubMed ID: 1540881
[TBL] [Abstract][Full Text] [Related]
12. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Kim NK; Park YS; Heo DS; Suh C; Kim SY; Park KC; Kang YK; Shin DB; Kim HT; Kim HJ
Cancer; 1993 Jun; 71(12):3813-8. PubMed ID: 8508349
[TBL] [Abstract][Full Text] [Related]
13. Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer.
Park JO; Chung HC; Cho JY; Rha SY; You NC; Kim JH; Noh SH; Kim CB; Min JS; Kim BS; Roh JK
Am J Clin Oncol; 1997 Oct; 20(5):484-9. PubMed ID: 9345333
[TBL] [Abstract][Full Text] [Related]
14. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
Cocconi G; Bella M; Zironi S; Algeri R; Di Costanzo F; De Lisi V; Luppi G; Mazzocchi B; Rodinò C; Soldani M
J Clin Oncol; 1994 Dec; 12(12):2687-93. PubMed ID: 7989945
[TBL] [Abstract][Full Text] [Related]
15. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer.
Chang HM; Jung KH; Kim TY; Kim WS; Yang HK; Lee KU; Choe KJ; Heo DS; Bang YJ; Kim NK
Ann Oncol; 2002 Nov; 13(11):1779-85. PubMed ID: 12419751
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
